Amplifica Holdings Group Inc. has closed a US$11.8 million series A preferred stock financing, the funds from which will be used to advance the development of its proprietary compounds for the treatment of androgenic alopecia in males and females.
Maxinovel Pharmaceuticals Inc. raised ¥100 million ($13.8 million) in a series C+ round to develop its candidates for acute myeloid leukemia, solid tumors, and autoimmune diseases.
Deepull Diagnostics SL has raised €13 million (US$12.71 million) in a series B round to advance development of a PCR-based rapid diagnostic for the early diagnosis of sepsis and acute infections.
RSS
